판토프라졸

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Known hypersensitivity to pantoprazole or other substituted benzimidazole PPIs
• Intramuscular (IM) or Subcutaneous (SQ) administration (parenteral form must be given IV)
• Intramuscular (IM) administration
• Subcutaneous (SC) administration

이상반응

• Diarrhea
• Headache (reported in humans)
• Hyperglycemia (rare, ~1% in humans)
• Injection site reactions (thrombophlebitis, abscess) with IV use
• Potential increased risk of community-acquired pneumonia (noted in human literature)
• Diarrhoea
• Headache
• Hyperglycaemia (rare)
• Increased risk of pneumonia
• Thrombophlebitis (associated with IV injection)

약물 상호작용

• Ketoconazole, itraconazole, iron, ampicillin esters · Decreased drug absorption due to increased gastric pH (these drugs require an acidic environment for optimal absorption)
• Sucralfate · May decrease the bioavailability of orally administered pantoprazole
• Warfarin · Pantoprazole may increase the anticoagulant effect
• Itraconazole · Decreased absorption of itraconazole due to increased gastric pH · moderate
• Ketoconazole · Decreased absorption of ketoconazole due to increased gastric pH · moderate

모니터링

• Efficacy (resolution of clinical signs, improvement in gastric pH)
• Adverse effects (vomiting, diarrhea)
• Injection site reactions (thrombophlebitis, abscess) if used IV
• Resolution of clinical signs (vomiting, melena, regurgitation)
• Gastric pH (in critical care settings)
• IV catheter site for signs of thrombophlebitis

과용량

Limited information available in veterinary species. A single oral dose of 887 mg/kg was lethal in dogs, causing acute toxic signs including ataxia, hypo-activity, and tremor. In humans, single oral overdoses up to 600 mg have been reported without adversity. In the event of a large overdose, contact an animal poison control center for guidance.